2,4-ds-PBN Combination Therapy for Temozolomide-Resistant Gliomas
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for drug-resistant gliomas, particularly those resistant to temozolomide, are ineffective, and there is a need for therapies that can cross the blood-brain barrier to target glioma cells effectively.
Innovation Solution
The use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in combination with temozolomide to inhibit the vascularization, growth, or spread of temozolomide-resistant gliomas, administered through routes that allow passage across the blood-brain barrier, such as enteral, intravenous, or intra-arterial methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 2,4-ds-PBN is used to treat temozolomide-resistant gliomas, then tumor growth and spread are inhibited and survival rates increase, but the drug must overcome the blood-brain barrier to reach the tumor effectively
Solution Approach 1:
The patent modifies the chemical structure of PBN by introducing two sulfonyl groups at the 2,4 positions of the phenyl ring, changing the molecule from lipophilic to hydrophilic. This parameter change in chemical structure enables 2,4-ds-PBN to cross the blood-brain barrier effectively while maintaining anti-glioma activity, resolving the contradiction between effectiveness and barrier penetration.
2Ease of operation
If conventional chemotherapy alone is used, then treatment is simple, but drug resistance develops and treatment becomes ineffective
Solution Approach 1:
The patent combines 2,4-ds-PBN with temozolomide in a synergistic therapy regimen. This merging of two agents with different mechanisms of action (free radical scavenging by PBN and DNA alkylation by temozolomide) overcomes drug resistance while maintaining treatment feasibility, resolving the contradiction between operational simplicity and therapeutic reliability.
3Reliability
If post-treatment with PBN is used, then some tumor growth reduction is achieved, but the effect is significantly reduced compared to pre-treatment
Solution Approach 1:
The patent emphasizes pre-treatment administration of 2,4-ds-PBN before temozolomide therapy to maximize effectiveness. This preliminary action primes the tumor cells and enhances subsequent temozolomide efficacy, preventing resistance development and achieving superior tumor growth reduction compared to post-treatment approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of 2,4-ds-PBN and temozolomide significantly inhibits the growth and spread of temozolomide-resistant gliomas, increasing survival rates and reducing tumor volumes in animal models, even in cases where previous therapies have failed.
Implementation Method 1
administration through a route requiring subsequent passage of 2,4-ds-PBN across the blood brain barrier
Implementation Method 2
PBN administration as a pretreatment was found to clearly induce a decrease in growth rate and tumor regression as well as preventing angiogenesis
Implementation Method 3
The mechanism of action of PBN in glioma treatment involves trapping free radicals and inducing oxidative stress in tumor cells
Data Source
Figure 1~2
Figure 3
Figure 4~5A
AI summary
The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4- ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.